AC
WST icon

AlphaCore Capital’s West Pharmaceutical WST Stock Holding History

AlphaCore Capital’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
+719
New +$220K ﹤0.01% 984

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

AlphaCore Capital's WST Position: Q2 2026 in Review

AlphaCore Capital opened a new position in West Pharmaceutical (WST) in Q2 2026: 719 shares worth $258K. The stake represents ﹤0.01% of the portfolio and ranks #984 among its holdings.

830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • AlphaCore Capital held 719 shares of West Pharmaceutical worth $258K as of Q2 2026.
  • West Pharmaceutical was a new AlphaCore Capital position in Q2 2026.
  • West Pharmaceutical made up ﹤0.01% of AlphaCore Capital's portfolio in Q2 2026, its #984 holding.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.